Table 2. Univariate and multivariate COX analyses for overall RFS of HCC patients.
| Variables | N=383 | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Gender (female/male) | 46/337 | 0.772 (0.502–1.188) | 0.240 | |||
| Age, years (>50/≤50) | 189/194 | 0.899 (0.694–1.166) | 0.424 | |||
| Smoke (yes/no) | 128/255 | 1.406 (1.072–1.844) | 0.014 | – | – | |
| Drink (yes/no) | 76/307 | 1.283 (0.933–1.765) | 0.125 | |||
| Diabetes (yes/no) | 34/349 | 1.522 (1.002–2.309) | 0.049 | – | – | |
| Cirrhosis (yes/no) | 253/130 | 1.127 (0.849–1.495) | 0.407 | |||
| Ascites (yes/no) | 45/338 | 1.191 (0.791–1.793) | 0.403 | |||
| Tumor diameter, cm (>5/≤5) | 158/225 | 2.083 (1.603–2.707) | <0.001 | 1.471 (1.106–1.958) | 0.008 | |
| Tumor number (multiple/single) | 113/270 | 2.276 (1.740–2.978) | <0.001 | 2.113 (1.610–2.772) | <0.001 | |
| Vascular invasion (yes/no) | 138/245 | 1.823 (1.402–2.371) | <0.001 | – | – | |
| Child-Pugh grade (B/A) | 25/358 | 1.203 (0.752–1.926) | 0.441 | |||
| MELD score (>2/≤2) | 305/78 | 1.216 (0.858–1.723) | 0.271 | |||
| BCLC stage (B-C/0~A) | 209/174 | 1.736 (1.328–2.270) | <0.001 | – | – | |
| Pathological differentiation (poor-moderate/well) | 315/68 | 1.971 (1.346–2.886) | <0.001 | 1.688 (1.136–2.507) | 0.010 | |
| AFP, ng/mL (>400/≤400) | 123/260 | 1.455 (1.109–1.909) | 0.007 | – | – | |
| HBV-DNA, copies/mL (>1,000/≤1,000) | 181/202 | 1.216 (0.938–1.577) | 0.139 | |||
| Fibrinogen, g/mL (>3.52/≤3.52) | 110/273 | 1.911 (1.455–2.509) | <0.001 | 1.519 (1.121–2.058) | 0.007 | |
| NLR (>1.92/≤1.92) | 188/195 | 1.279 (0.986–1.658) | 0.063 | – | – | |
| dNLR (≤2.02/>2.02) | 272/111 | 1.055 (0.784–1.420) | 0.722 | |||
| PLR (>60.28/≤60.28) | 334/49 | 0.822 (0.571–1.184) | 0.292 | |||
| LMR (≤3.84/>3.84) | 184/199 | 1.685 (1.297–2.189) | <0.001 | 1.324 (1.005–1.745) | 0.046 | |
| GPR (>0.33/≤0.33) | 204/179 | 1.692 (1.294–2.213) | <0.001 | – | – | |
| SII (>289.28/≤289.28) | 206/177 | 1.361 (1.047–1.769) | 0.021 | – | – | |
| PNI (≤47.6/>47.6) | 160/223 | 1.531 (1.180–1.986) | 0.001 | – | – | |
| APRI (>0.17/≤0.17) | 254/129 | 1.576 (1.170–2.124) | 0.003 | – | – | |
| ANRI (>9.39/≤9.39) | 249/134 | 1.416 (1.061–1.891) | 0.018 | – | – | |
| ALRI (>25.69/≤25.69) | 152/231 | 1.268 (0.978–1.646) | 0.074 | – | – | |
| ALBI (>−2.79/≤−2.79) | 248/135 | 1.703 (1.273–2.278) | <0.001 | – | – | |
| FIB-4 (>1.46/≤1.46) | 239/144 | 1.352 (1.020–1.791) | 0.036 | – | – | |
| S-index (>0.25/≤0.25) | 172/211 | 1.885 (1.452–2.448) | <0.001 | 1.813 (1.385–2.374) | <0.001 | |
MELD, Model for End-stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; GPR, gamma-glutamyl transpeptidase-to-platelet ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; APRI, aspartate transaminase-to-platelet count ratio index; ANRI, aspartate transaminase-to-neutrophil ratio index; ALRI, aspartate transaminase-to-lymphocyte ratio index; ALBI, albumin-bilirubin; FIB-4, fibrosis index based on the four factors; RFS, recurrence-free survival.